Omne Possibile

Omne Possibile is a private synthetic biology company developing xeno nucleic acid (XNA) technologies intended to outperform conventional DNA and RNA systems across multiple end markets, including healthcare. In biomedicine, the company has highlighted XNA building blocks for improved messenger therapeutics as an initial focus, alongside broader XNA development capabilities spanning chemical synthesis, genetics, directed evolution of enzymes and genomes, automated molecular design, and bioproduction pathways. The company was launched in 2021 by a group of European synthetic biology founders and has operated from Basel, Switzerland, with an R&D presence in Leuven, Belgium. Omne Possibile appears to be an early-stage platform company rather than a clinical-stage drug developer, and public evidence for named therapeutic programs or clinical trials is limited. Its broader business positioning also includes non-healthcare applications such as information storage and smart materials.